First PREMIER Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

First PREMIER Bank’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-13	Closed	-$5K	–	504
2024 Q1	$5K	Buy	+13	New	+$5.5K	﹤0.01%	378
2023 Q2	–	Sell	-125	Closed	-$39K	–	403
2023 Q1	$39K	Hold	125	–	–	0.01%	250
2022 Q4	$36K	Hold	125	–	–	0.01%	245
2022 Q3	$36K	Hold	125	–	–	0.01%	244
2022 Q2	$35K	Hold	125	–	–	0.01%	261
2022 Q1	$33K	Hold	125	–	–	0.01%	256
2021 Q4	$27K	Buy	+125	New	+$24.3K	0.01%	262

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

First PREMIER Bank's VRTX Position: Q2 2024 in Review

First PREMIER Bank sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 13 shares — an estimated $5K sold.

First PREMIER Bank first reported a position in VRTX in Q4 2021 and held it in 7 quarters. The position peaked at $39K in Q1 2023. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

First PREMIER Bank reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
First PREMIER Bank sold 13 Vertex Pharmaceuticals shares in Q2 2024, an estimated $5K.
First PREMIER Bank first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 7 quarters.
First PREMIER Bank's Vertex Pharmaceuticals position peaked at $39K in Q1 2023.
1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on First PREMIER Bank's 13F filing for Q2 2024, filed 17 Jul 2024.